Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 29 results.
User Information
Export Records
  1. 1.   The indenoisoquinoline LMP517: a novel antitumor agent targeting both TOP1 and TOP2
  2. Marzi, Laetitia; Sun, Yilun; Huang, Shar-Yin N; James,Amy; Difilippantonio,Simone; Pommier, Yves
  3. Molecular cancer therapeutics. 2020, AUG; 19(8): 1589-1597.
  1. 2.   Structural genomic changes during mammalian ontogeny: a new dimension
  2. Shiao, Y. H.; Anderson, L. M.
  3. Epigenomics. 2012, Feb; 4(1): 1-4.
  1. 3.   Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
  2. Kummar, S.; Chen, A.; Ji, J. P.; Zhang, Y. P.; Reid, J. M.; Ames, M.; Jia, L.; Weil, M.; Speranza, G.; Murgo, A. J.; Kinders, R.; Wang, L. H.; Parchment, R. E.; Carter, J.; Stotler, H.; Rubinstein, L.; Hollingshead, M.; Melillo, G.; Pommier, Y.; Bonner, W.; Tomaszewski, J. E.; Doroshow, J. H.
  3. Cancer Research. 2011, Sep; 71(17): 5626-5634.
  1. 4.   N-Hydroxyethyl-4-aza-didehydropodophyllotoxin derivatives as potential antitumor agents
  2. Kumar, A.; Kumar, V.; Alegria, A. E.; Malhotra, S. V.
  3. European Journal of Pharmaceutical Sciences. 2011, Sep; 44(1-2): 21-26.
  1. 5.   Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 alpha in Advanced Solid Tumors
  2. Kummar, S.; Raffeld, M.; Juwara, L.; Horneffer, Y.; Strassberger, A.; Allen, D.; Steinberg, S. M.; Rapisarda, A.; Spencer, S. D.; Figg, W. D.; Chen, X. H.; Turkbey, I. B.; Choyke, P.; Murgo, A. J.; Doroshow, J. H.; Melillo, G.
  3. Clinical Cancer Research. 2011, Aug; 17(15): 5123-5131.
  1. 6.   Histone yH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
  2. Redon, C. E.; Nakamura, A. J.; Zhang, Y. W.; Ji, J. P.; Bonner, W. M.; Kinders, R. J.; Parchment, R. E.; Doroshow, J. H.; Pommier, Y.
  3. Clinical Cancer Research. 2010, Sep; 16(18): 4532-4542.
  1. 7.   Polo-box domain: a versatile mediator of polo-like kinase function
  2. Park, J. E.; Soung, N. K.; Johmura, Y.; Kang, Y. H.; Liao, C.; Lee, K. H.; Park, C. H.; Nicklaus, M. C.; Lee, K. S.
  3. Cellular and Molecular Life Sciences. 2010, Jun; 67(12): 1957-1970.
  1. 8.   The DNA binding and 3'-end preferential activity of human tyrosyl-DNA phosphodiesterase
  2. Dexheimer, T. S.; Stephen, A. G.; Fivash, M. J.; Fisher, R. J.; Pommier, Y.
  3. Nucleic Acids Research. 2010, Apr; 38(7): 2444-2452.
  1. 9.   Exon Array Analyses across the NCI-60 Reveal Potential Regulation of TOP1 by Transcription Pausing at Guanosine Quartets in the First Intron
  2. Reinhold, W. C.; Mergny, J. L.; Liu, H. F.; Ryan, M.; Pfister, T. D.; Kinders, R.; Parchment, R.; Doroshow, J.; Weinstein, J. N.; Pommier, Y.
  3. Cancer Research. 2010, Mar; 70(6): 2191-2203.
  1. 10.   Monitoring Drug-Induced gamma H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
  2. Wang, L. H.; Pfister, T. D.; Parchment, R. E.; Kummar, S.; Rubinstein, L.; Evrard, Y. A.; Gutierrez, M. E.; Murgo, A. J.; Tomaszewski, J. E.; Doroshow, J. H.; Kinders, R. J.
  3. Clinical Cancer Research. 2010, Feb; 16(3): 1073-1084.
  1. 11.   Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
  2. Rapisarda, A.; Shoemaker, R. H.; Melillo, G.
  3. Cell Cycle. 2009, Dec; 8(24): 4040-4043.
  1. 12.   4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate) (NSC 88915) and Related Novel Steroid Derivatives as Tyrosyl-DNA Phosphodiesterase (Tdp1) Inhibitors
  2. Dexheimer, T. S.; Gediya, L. K.; Stephen, A. G.; Weidlich, I.; Antony, S.; March, C.; Interthal, H.; Nicklaus, M.; Fisher, R. J.; Njar, V. C.; Pommier, Y.
  3. Journal of Medicinal Chemistry. 2009 52(22): 7122-7131.
  1. 13.   Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
  2. Rapisarda, A.; Hollingshead, M.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Gehrs, B.; Raffeld, M.; Kinders, R. J.; Parchment, R.; Anver, M. R.; Shoemaker, R. H.; Melillo, G.
  3. Molecular Cancer Therapeutics. 2009 8(7): 1867-1877.
  1. 14.   Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1
  2. Antony, S.; March, C.; Stephen, A. G.; Thibaut, L.; Agama, K. K.; Fisher, R. J.; Pommier, Y.
  3. Nucleic Acids Research. 2007 35(13): 4474-4484.
  1. 15.   Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites
  2. March, C.; Krajewski, K.; Lee, H. F.; Antony, S.; Johnson, A. A.; Amin, R.; Roller, P.; Kvaratskhelia, M.; Pommier, Y.
  3. Nucleic Acids Research. 2006, Oct; 34(18): 5157-5165.
  1. 16.   Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells
  2. Brantley, E.; Antony, S.; Kohlhagen, G.; Meng, L. H.; Agama, K.; Stinson, S. F.; Sausville, E. A.; Pommier, Y.
  3. Cancer Chemotherapy and Pharmacology. 2006, Jul; 58(1): 62-72.
  1. 17.   Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis
  2. Dorjsuren, D.; Burnette, A.; Gray, G. N.; Chen, X. L.; Zhu, W. M.; Roberts, P. E.; Currens, M. J.; Shoemaker, R. H.; Ricciardi, R. P.; Sei, S.
  3. Antiviral Research. 2006, JAN; 69(1): 9-23.
  1. 18.   Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-4
  2. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Hamel, E.; Schmidt, J. M.; Pettitt, R. K.
  3. Journal of Medicinal Chemistry. 2005, JUN 16; 48(12): 4087-4099.
  1. 19.   Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
  2. Rapisarda, A.; Zalek, J.; Hollingshead, M.; Braunschweig, T.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Hewitt, S. M.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004, OCT 1; 64(19): 6845-6848.
  1. 20.   Autoreactive T cells recognize multiple epitopes on DNA topoisomerase I in sytemic sclerosis patients and in healthy controls
  2. Hu, P. Q.; Oriss, T.; Medsger, T.; Wright, T.
  3. Faseb Journal. 2004 18(5, Suppl. S): A836-A836.
  1. 21.   A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy
  2. Cragg, G. M.; Newman, D. J.
  3. Journal of Natural Products. 2004 67(2): 232-244.
  1. 22.   Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications
  2. Rapisarda, A.; Uranchimeg, B.; Sordet, O.; Pommier, Y.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004 64(4): 1475-1482.
  1. 23.   Identification of small molecule inhibitors of hypoxia- inducible factor 1 transcriptional activation pathway
  2. Rapisarda, A.; Uranchimeg, B.; Scudiero, D. A.; Selby, M.; Sausville, E. A.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2002 62(15): 4316-4324.
  1. 24.   Cellular pharmacology studies of shikonin derivatives
  2. Chen, X.; Yang, L.; Oppenheim, J. J.; Howard, O. M. Z.
  3. Phytotherapy Research. 2002 16(3): 199-209.
  1. 25.   Use of COMPARE analysis to discover new natural product drugs: Isolation of camptothecin and 9-methoxycamptothecin from a new source
  2. Zhou, B. N.; Hoch, J. M.; Johnson, R. K.; Mattern, M. R.; Eng, W. K.; Ma, J.; Hecht, S. M.; Newman, D. J.; Kingston, D. G. I.
  3. Journal of Natural Products. 2000 63(9): 1273-1276.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel